ASH 2017: Dr. Thomas Kipps on the ROR1 Antibo... - CLL Support

CLL Support
15,416 members24,815 posts

ASH 2017: Dr. Thomas Kipps on the ROR1 Antibody, Cirmtuzumab


Extremely exciting research into a “new” antibody targeting CLL cells. Note that it may be of particular interest both because of its promising Phase 1 trial results AND because of its long half life.

Also, it is being developed by Dr. Kipps and team at the Moore Cancer Center at UCSD and NOT Big Pharma. This may bode well for access for those with no or inadequate insurance or in countries with government-run universal healthcare programs.

1 Reply

I would love to say I used to have CLL. Thanks for the new information. Sally

You may also like...